文献速递生殖医学

来曲唑与枸橼酸氯米芬治疗多囊卵巢综合征不孕女性的双盲随机对照试验

Double-blind randomized controlled trial of letrozole versus clomiphene citrate in subfertile women with polycystic ovarian syndrome.
PubMed 文献 · Hum Reprod · 2017-01-01

这项双盲随机对照试验纳入159例无排卵性多囊卵巢综合征不孕女性,按1:1随机分配至来曲唑组(80例)或枸橼酸氯米芬组(79例)。意向性分析显示来曲唑组临床妊娠率61.2%显著高于氯米芬组43.0%(P=0.022),来曲唑组至妊娠所需治疗周期中位数4个显著少于氯米芬组6个(log rank P=0.038),活产率两组无统计学差异(P=0.089)。

要点

  • 来曲唑组临床妊娠率61.2%显著高于氯米芬组43.0%(P=0.022)。
  • 来曲唑组至妊娠所需周期中位数4个,显著少于氯米芬组6个(log rank P=0.038)。
  • 活产率来曲唑组48.8% vs 氯米芬组35.4%,无统计学差异(P=0.089)。

核心结论

  • 来曲唑作为一线促排卵药物治疗无排卵性多囊卵巢综合征不孕女性,临床妊娠率显著高于枸橼酸氯米芬,至妊娠时间更短。
  • 活产率两组无统计学差异,但来曲唑组有升高趋势。

研究设计与样本

  • 双盲随机对照试验,2007年4月至2014年6月纳入159例无排卵性多囊卵巢综合征不孕女性。
  • 按1:1随机分配至枸橼酸氯米芬组(n=79)或来曲唑组(n=80),按体重指数(<30和30-35 kg/m2)分层,混合区组随机化。

主要发现

  • 意向性分析159例中,4例治疗前妊娠,6例失访,剩余149例(氯米芬组74例,来曲唑组75例)至少完成第一周期治疗。
  • 来曲唑组临床妊娠率61.2%显著高于氯米芬组43.0%(P=0.022;绝对差[95%CI] 18%[3-33%])。
  • 至妊娠所需治疗周期中位数来曲唑组4个[3-5]显著少于氯米芬组6个[4-7](log rank P=0.038)。
  • 活产率来曲唑组48.8% vs 氯米芬组35.4%,无统计学差异(P=0.089)。
  • 交叉后妊娠率和活产率来曲唑组(n=45)分别为28.9%和24.4%,氯米芬组(n=31)分别为22.6%和19.4%,均无统计学差异(P=0.539和P=0.601)。

关键数值与推荐

  • 来曲唑起始剂量2.5 mg每日一次,氯米芬起始剂量50 mg每日一次。
  • 无反应者剂量加倍,持续至妊娠或最多6个排卵周期,无反应者经6周洗脱期后交叉至另一治疗。

临床怎么用

  • 作者认为,本试验结果为来曲唑作为多囊卵巢综合征女性一线促排卵药物优于枸橼酸氯米芬提供了更有效和令人信服的证据,妊娠率提高40%且至妊娠时间更短。
  • 作者认为,本试验参与者能良好代表欧洲及全球接受生育治疗的多囊卵巢综合征不孕人群,结果可在全球临床实践中推广。

局限性

  • 本试验可能的一个局限性是排除了体重指数>35 kg/m2的多囊卵巢综合征女性,限制了结果在该亚组中的适用性。
  • 但该组女性因相关挑战和风险,在多数生育中心(尤其欧洲)通常被排除在治疗之外。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Would letrozole as a primary ovulation induction agent generate better pregnancy rates than clomiphene citrate (CC) in subfertile women with anovulatory polycystic ovarian syndrome (PCOS)? SUMMARY ANSWER: Participants receiving letrozole as a primary treatment achieved a significantly (P = 0.022) higher clinical pregnancy rate per patient (61.2%) compared to CC (43.0%). WHAT IS KNOWN ALREADY: According to a recent Cochrane systematic review (2014), letrozole appears to improve live-birth (LB) and pregnancy rates in anovulatory women with PCOS, compared to CC. However, the review concluded that the quality of evidence was low due to poor reporting of study methods and possible publication bias. STUDY DESIGN, SIZE, DURATION: This double-blind randomized controlled trial (RCT) included 159 participants between April 2007 and June 2014. Subjects were randomly allocated to either CC (n = 79) or letrozole (n = 80) in a 1:1 ratio. Both drugs were encapsulated to look identical. Randomization was performed in mixed blocks and stratified by patients' BMI (<30 and 30-35 kg/m2). PARTICIPANTS/MATERIALS, SETTING, METHODS: The trial included subfertile women diagnosed with PCOS. Treatment started with one tablet (CC 50 mg, letrozole 2.5 mg) increasing to two in non-responders and continuing until pregnancy or for up to six ovulatory cycles. Non-responders were crossed over to the other treatment after a 6-week break. Cycles were initially monitored with ultrasound follicle tracking then mid-luteal serum progesterone measurement in subsequent cycles. MAIN RESULTS AND THE ROLE OF CHANCE: Amongst the 159 participants included in the intention-to-treat analysis, four women conceived before treatment and six were lost-to-follow-up. The remaining 149 participants (74 on CC and 75 on letrozole) completed at least the first treatment. Women receiving letrozole achieved a significantly (P = 0.022; absolute difference [95% confidence interval] 18% [3-33%]) higher pregnancy rate (61.%) than those on CC (43%). The median number of treatment cycles received until pregnancy was significantly (log rank P = 0.038) smaller with letrozole (4[3-5] cycles) compared to CC (6[4-7] cycles). LB rates were not statistically (P = 0.089) different between the two groups, although there was a trend towards higher rates on letrozole (48.8%) compared to CC (35.4%). After the crossover, pregnancy and LB rates on letrozole (n = 45; 28.9 and 24.4%, respectively) were not statistically (P = 0.539 and P = 0.601) different from CC (n = 31; 22.6 and 19.4%). LIMITATIONS, REASONS FOR CAUTION: One possible limitation of this trial may be the exclusion of PCOS women with BMI > 35 kg/m2, which would limit the applicability of the results in this subgroup of PCOS. However, this group of women are generally excluded from treatment in the majority of fertility centres, especially in Europe, due to the associated challenges and risks. WIDER IMPLICATIONS OF THE FINDINGS: The results of this trial are consistent with the recent Cochrane systematic review. However, with its robust design, the current RCT provides more valid and compelling evidence for the superiority of letrozole over CC as a primary ovulation induction agent in PCOS women with 40% increase in pregnancy rates and with a shorter time-to-pregnancy. Furthermore, the participants in this RCT are a good representation of subfertile PCOS population receiving fertility treatment in Europe and worldwide. The results are therefore globally generalizable for clinical practice. STUDY FUNDING/COMPETING INTEREST(S): This RCT was mainly funded by the R&D Funding Scheme of Derby Hospitals NHS Foundation Trust. The study also received funds from School of Medicine, University of Nottingham. The Trust R&D department was involved in the development of the protocol and the running of the trial. The trial was sponsored and monitored by the University of Nottingham. The authors have no conflicts of interest. TRIAL REGISTRATION NUMBER: www.Clinicaltrials.gov: NCT00478504. TRIAL REGISTRATION DATE: Registration was verified on 23/05/2007. DATE OF FIRST PATIENT'S ENROLMENT: 25/04/2007.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Amer SA, Smith J, Mahran A, et al. Double-blind randomized controlled trial of letrozole versus clomiphene citrate in subfertile women with polycystic ovarian syndrome. Hum Reprod. 2017. PMID: 28854590. doi:10.1093/humrep/dex227

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。